Clinical trials: Myelodysplastic Neoplasm
Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy
A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
This is a post-marketing surveillance study conducted as part of the Risk Management Plan (RMP) for South Korea, to evaluate the safety and effectiveness of iptacopan in real-world clinical settings for the treatment of either…
- Trial name
- NCT07416162
- Where
- 3 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndromes
Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies characterized by cytopenia(s), dysplasia in one or more major myeloid cell lines and progression to acute leukemia.
- Trial name
- MODIFY (NCT03621241)
- Testing
- Flow cytometry
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Acute Myeloid Leukemia, Myelodysplastic Syndrome
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
The purpose of this research study is to determine the safety of the combination of RAD001 and PKC412 as a cancer treatment, and to establish the highest dose of RAD001 that can be given in conjunction with PKC412.
- Trial name
- NCT00819546
- Testing
- RAD001, PKC412
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Richard Stone, MD
Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of iadademstat when given together with azacitidine and venetoclax in treating patients with newly diagnosed acute myeloid leukemia (AML).
- Trial name
- NCT06357182
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Myelomonocytic Leukemia
Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia
The study aims to assess the activity of decitabine in the treatment of CMML.
- Trial name
- DECI2009 (NCT01251627)
- Testing
- Decitabine
- Where
- 21 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche-ETS
Clonal Mast Cell Disease, KIT D816V Mutation
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
- Conditions
- Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
- Trial name
- POLARIS (NCT07143669)
- Testing
- Screening
- Where
- 26 sites in United States, Belgium
- Volunteers
- 750 people
- Sponsor
- Blueprint Medicines Corporation
B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolumab, and cemiplimab in treating patients with multiple myeloma, acute…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome
- Trial name
- NCT03017820
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Mayo Clinic
Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase
Haploid Allogeneic Transplant Using the CliniMACS System
To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.
- Conditions
- Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL)
- Trial name
- NCT00185679
- Testing
- CliniMACS System
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ginna Laport
AML, Acute Myeloid Leukemia
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid…
- Conditions
- AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- CertainT-1 (NCT06834282)
- Testing
- CER-1236, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- CERo Therapeutics Holdings, Inc.
Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML)
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are…
- Conditions
- Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia(JMML)
- Trial name
- NCT00186823
- Testing
- Miltenyi Biotec CliniMACS, Stem Cell Transplantation, TBI, systemic chemotherapy and antibodies as follows:
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- St. Jude Children's Research Hospital
Advanced Malignancies That Harbor IDHR132 Mutations
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
- Trial name
- NCT02381886
- Testing
- IDH305
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute
Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
Patients receiving allogeneic stem cell transplantation for hematological malignancies who suffer a relapse of their disease post-transplant have limited treatment options and a poor prognosis.
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, Leukemia, Myelocytic, Chronic
- Trial name
- NCT00859586
- Testing
- Miltenyi Magnetic cell sorter for CD3
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hematology, MDS
Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
This is an open label extension study of romiplostim for treatment of thrombocytopenia (platelet count ≤ 50 x 10^9/L) in MDS subjects.
- Conditions
- Hematology, MDS, Myelodysplastic Syndromes, Thrombocytopenia
- Trial name
- NCT00472290
- Testing
- Romiplostim (formerly AMG 531)
- Volunteers
- 72 people
- Sponsor
- Amgen
Multiple Myeloma, Myelodysplastic Syndromes
Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide
This is a non-intervention, prospective, open-label and observational clinical trial. The researchers plan to recruit at least 50 qualified patients.
- Conditions
- Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma
- Trial name
- NCT06069024
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Qianfoshan Hospital
Acute Leukemia, Chronic Myeloproliferative Disease
A Phase I Trial of ZIO-101 in Hematologic Cancers
This study uses a new investigational (not yet approved by the FDA for widespread use) drug called ZIO-101, an organic arsenical.
- Conditions
- Acute Leukemia, Chronic Myeloproliferative Disease, Chronic Lymphoproliferative Disease, Multiple Myeloma
- Trial name
- NCT00592046
- Testing
- ZIO-101 (Darinaparsin)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
Paroxysmal Nocturnal Hemoglobinuria
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
This study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as "study drugs".
- Trial name
- NCT07154745
- Testing
- Pozelimab, Cemdisiran
- Where
- 20 sites in Brazil, Canada and 5 more
- Volunteers
- 35 people
- Sponsor
- Regeneron Pharmaceuticals
Anemia, Myelodysplastic Syndromes
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
The primary objective of this study is to determine a safe, tolerable and effective dose of sotatercept that results in the greatest frequency of improvement of anemia in patients diagnosed with low- or intermediate-1 risk…
- Conditions
- Anemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low to Intermediate-1 MDS
- Trial name
- NCT01736683
- Testing
- Sotatercept
- Where
- 20 sites in United States, France
- Volunteers
- 74 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain and Central Nervous System Tumors, Kidney Cancer
Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors
RATIONALE: Tubefeeding may help maintain good nutrition and lessen weight loss in younger patients receiving chemotherapy for cancer.
- Conditions
- Brain and Central Nervous System Tumors, Kidney Cancer, Leukemia, Liver Cancer
- Trial name
- NCT00624962
- Testing
- nutritional intervention, therapeutic nutritional supplementation
- Sponsor
- Vanderbilt University
Paroxysmal Nocturnal Hemoglobinuria
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
This is a multicenter, open-label study to evaluate the long-term safety, tolerability and efficacy of HSK39297. Adult patients with PNH who had previously received and completed HSK39297 study treatment will be included.
- Trial name
- NCT06745622
- Testing
- HSK39297 tablets
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
This study aims to assess the safety and efficacy of orally administered JBI-802 in subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis.
- Conditions
- Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Myeloproliferative Neoplasms (MPN)
- Trial name
- NCT07612280
- Testing
- JBI-802
- Where
- 7 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Jubilant Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.